RxDoctor Payments Data

Cynthia Chambless, MD

Family Medicine · Macon, GANPI 1063577500

Payments from drug & device makers

$6,907in general payments, 2019–2025

Across 379 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$959
  • Boehringer Ingelheim$639
  • Lilly USA, LLC$558
  • Amgen$438
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,907 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$127,142
Medicare patients
264
Services billed
2,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$120,396
MounjaroTirzepatide42$54,670
FarxigaDapagliflozin Propanediol55$39,742
EliquisApixaban43$29,472
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$28,574
MyrbetriqMirabegron31$20,814
TrulicityDulaglutide16$18,048
JanuviaSitagliptin Phosphate16$17,867
KerendiaFinerenone15$13,075
SynthroidLevothyroxine Sodium88$9,337
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$5,420
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,077
Rosuvastatin Calcium394$4,685
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen151$4,662
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$3,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$959$120,39696 claims
Lilly USA, LLCMounjaro, Trulicity$558$72,71858 claims
AstraZenecaFarxiga$1,093$39,74255 claims
GSKTrelegy Ellipta, Anoro Ellipta$79$33,65136 claims
PfizerEliquis$386$29,47243 claims
Astellas Pharma US IncMyrbetriq$162$20,81431 claims
MerckJanuvia$206$17,86716 claims
BayerKerendia$118$13,07515 claims
AbbVieSynthroid$1,031$9,33788 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$42$1,998182 claims
Almatica Pharma LLCSertraline Hcl$13$65795 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →